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Abstract: Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available 
for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% 
are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, 
and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by 
enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and 
remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering 
superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 
0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOP-
lowering compared with latanoprost, with weighted mean difference in IOP reduction documented 
in one meta-analysis of 2.59% to 5.60% from 1- to 6-months study duration. PGAs reduce IOP 
further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or tra-
voprost formulated with timolol 0.5% and administered once daily are superior to monotherapy 
of its constituent parts. PGA have near absence of systemic side effects, although do have other 
commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found 
more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular 
pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administra-
tion and near absence of systemic side effects enhances tolerance and compliance. PGAs are often 
prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.
Keywords: prostaglandin analog, glaucoma, ocular hypertension, latanoprost, bimatoprost, 
travoprost
Introduction
Glaucoma is a common and potentially blinding ocular disease of multifactorial 
  etiology. It is characterized by progressive acquired loss of retinal ganglion cells leading 
to optic nerve atrophy and visual field deficits. An estimated 60.5 million people will 
have open-angle and angle-closure glaucoma by 2010, increasing to 79.6 million by 
2020.1 Elevated intraocular pressure (IOP) is an important and modifiable risk factor 
for the development and progression of glaucoma.2 For each mmHg reduction in IOP 
estimated progression risk decreased by approximately 10%. A 30% IOP reduction has 
been shown to slow the rate of visual field progression among normal tension glaucoma 
(NTG) subjects.3 The Ocular Hypertension Treatment Study (OHTS) confirmed that a 
reduction of 20% is an acceptable response to treatment in ocular hypertension (OH), 
and the risk of developing optic disc cupping and/or visual field loss in such cases 
decreased from 9.5% to 4.4%.4 However, the magnitude of IOP reduction required for Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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an   individual is dependent on a number of factors including 
IOP level at which optic nerve damage occurs, the rate and 
extent of glaucomatous damage, patient life expectancy, 
and presence of other risk factors for glaucoma.5,6 With 
disease progression, the target IOP may change and is thus 
not static.
As newer agents with increased efficacy and tolerability 
are introduced into the armamentarium of topical ocular 
hypotensive medications, a new era of glaucoma manage-
ment and declining glaucoma surgery rates is evolving.7 
Topical β-adrenergic antagonists (both selective and non-
selective derivatives) were initially introduced in 1978,7 
followed by selective α2-adrenergic receptor agonists in 
1988 and topical carbonic anhydrase inhibitors in 1995.7 
Isopropyl unoprostone (Rescula®; CIBA Vision Ophthal-
mics, Bulach, Switzerland) was the first topical prostaglan-
din F2α analog (PGA) commercially available, initially in 
Japan in 1994.7 Of the more currently used prostaglandin 
analogues (PGAs), latanoprost 0.005% (Xalatan®; Pfizer 
Inc., New York, NY) was launched in 1996, followed by 
bimatoprost 0.03% (Lumigan®; Allergan Inc., Irvine, CA) 
and travoprost 0.004% (Travatan®; Alcon Inc., Ft Worth, 
TX) in 2001.7 Latanoprost and travoprost are both ester 
prodrugs of prostaglandin F2α (PGF2α). Bimatoprost 
is the amide prodrug of 17-phenyl-PGF2α and has been 
described as a prostamide,5,8–11 although controversial.12–15 
This review will focus on the three most commonly used 
PGAs (latanoprost, travoprost and bimatoprost) for OH and 
open-angle glaucoma (OAG).
Pharmacodynamic properties  
of prostaglandin analogs
Latanoprost and travoprost are potent prodrug derivatives of 
naturally occurring PGF2α and highly selective FP prosta-
glandin receptor agonists. The chemical structure of travo-
prost differs from latanoprost (13,14-dihydro-17-phenyl-18, 
19, 20-trinor-PGF2α isopropyl ester) by having a phenoxy 
group at carbon-16 and a trifluoromethyl group at the meta 
position on the phenoxy ring.7,16 Travoprost is the isopropyl 
ester of a single enantiomer of fluprostenol.17 Hydrolysis of 
the isopropyl ester to a biologically free and active carboxylic 
acid enables corneal penetration and agonism of the G-protein 
coupled FP receptor.
Bimatoprost is a PGF2α analog where a neutral ethyl-
amide substituent replaces the carboxylic acid. It appears 
to mimic the activity of prostamides, a newly discovered 
class of naturally occurring substances with inherent IOP 
lowering properties biosynthesized from endocannabinoid 
anandamide by the enzyme COX-2.5,8–11,18,19 Bimatoprost 
increases outflow facility by 40% in human organ-cultured 
anterior segments within 48 hours of treatment and is 
blocked by AGN211334 a prostamide selective   antagonist.20 
Although bimatoprost is not regarded as a prodrug by 
some researchers,8,11 some human studies have detected 
bimatoprost free acid at levels high enough to activate the 
FP receptor.12–15 Lack of detection of the free acid at the site 
of action in other studies8,11 could be attributed to corneal 
esterase deficiency in some individuals, thus inability to 
convert the prodrug to the active free acid form.21
The free acids of latanoprost, bimatoprost and travoprost 
all fully and selectively activate the FP receptor relative to the 
naturally occurring agonist PGF2α, although receptor affinity 
is variable. Free acids of travoprost14,16 and bimatoprost14,15 
are, respectively, approximately 10 and 3 to 10 times more 
potent in activating the FP receptor than latanoprost free acid. 
Travoprost concentration of 0.004% is slightly lower than 
latanoprost at 0.005%, but probably represents a much higher 
dose on the dose-response curve.22 Bimatoprost concentration 
of 0.03% is 6 times that of latanoprost to allow sufficient 
conversion to its free acid to activate the FP receptor. Sub-
sensitivity at the FP receptor level from either desensitization 
or down-regulation of the FP receptor23,24 could account for 
the observed reduced efficacy or even IOP increase with 
combination PGA therapy or increased frequency of PGA 
administration.
The exact mechanisms of action of PGAs are not entirely 
clear. Primate studies have shown that PGAs reduce IOP by 
enhancing uveoscleral25–28 and trabecular outflow with little 
or no effect on aqueous humor formation or episcleral venous 
pressure.7,10,20,21,26,29–31 Initial IOP reduction with PGAs may 
also be attributed to ciliary muscle relaxation via FP recep-
tors, thus facilitating uveoscleral outflow.32 The presence of 
prostaglandins in trabecular meshwork cells31 and anterior 
segment organ cultures33 support a role in aqueous outflow 
regulation. Latanoprost acid infused human organ-cultured 
anterior segments significantly increased outflow facility at 
24 hours (67% vs 6% controls).29 Proposed superior effects 
on trabecular outflow compared to uveoscleral outflow with 
bimatoprost26 or travoprost28 could be accounted for by 
measurement technique.34
PGAs appear to regulate matrix metalloproteinases 
(MMP) and tissue inhibitors of matrix metalloproteinases 
(TIMP) to modulate trabecular outflow resistance. MMPs are 
neutral zinc-dependent endoproteinases involved with normal 
and pathologic remodeling of extracellular matrix. Increased 
expression of MMP-1, -3, -17, and -24 and TIMP-2, -3, -435 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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in human trabecular meshwork cell cultures treated with 
latanoprost acid for 24 hours, and MMP-1, -2, -336 in iris 
root, ciliary muscle, and adjacent sclera in monkeys may lead 
to hydrolysis of collagen types I and III (MMP-1), collagen 
IV and fibronectin (MMP-2), and collagen types III, IV, 
fibronectin and laminin (MMP-3), resulting in widening of 
the connective tissue-filled spaces among the ciliary muscle 
bundles37 and loss of trabecular meshwork (TM) extracellular 
matrix, hence increased outflow.29,36 Similar anterior segment 
morphologic changes among the different prostaglandins,38 
suggest similar mechanisms of action on uveoscleral or tra-
becular outflow.31 Studies to elucidate cellular mechanisms 
associated with PG-induced MMP secretion and alterations 
in calcium signaling pathways in the trabecular meshwork 
are ongoing.
A small (10% to 15%) nocturnal increase in aqueous flow 
and uveoscleral outflow has been found from PGA use.25,39,40 
Documented 24-hour efficacy of PGAs41–46 is important in 
reducing ischemic damage to the optic nerve caused by 
nocturnal episodes of systemic hypotension, especially in 
subjects with NTG. Topical β-blockers are unable to sup-
press aqueous secretion, hence reduce IOP, during sleep.47 
Enhanced aqueous flow may also act to carry nutrients and 
remove waste products, important in the maintenance of 
anterior segment health.21
Other effects
Reduced or increased ocular blood flow (OBF) may respec-
tively accelerate or prevent glaucomatous progression in 
some subjects. Latanoprost significantly increased pulsatile 
OBF in healthy volunteers,48,49 and OAG50,51 and NTG52–54 
subjects, although not consistently found.55 A randomized 
double-masked crossover study56 found a more favorable 
effect on ocular perfusion pressures (OPP) (which are directly 
related to OBF) with latanoprost than timolol.56 Using color 
Doppler ultrasound, Koz et al57 demonstrated that latanoprost, 
travoprost and bimatoprost increased blood flow velocity and 
OPP, and latanoprost and travoprost decreased the resistive 
index of the ophthalmic artery and central retinal artery 
(CRA). Alagoz et al58 found increased CRA blood flow with 
bimatoprost and travoprost use. Other studies have found no 
change in blood flow velocity or vascular resistivity of the 
retrobulbar vessels with latanoprost.59–60 It is unclear if the 
effects on ocular hemodynamic parameters are related to 
IOP decrease or an independent phenomenon. Observation 
of conjunctival and scleral hyperemia with PGAs suggests 
vasodilatory actions, but vasoconstrictory effects may occur, 
often at higher concentrations.
Pharmacokinetics of prostaglandin 
analogs
After administration of a single drop (30 µL) of tritium-labeled 
latanoprost 50 µg/mL (thus 1.5 µg of drug), the   maximum 
concentration of latanoprost averaged 32.6 ± 20.6 ng/mL 
at 2.5 hours.62 The elimination half-life of latanoprost acid 
from the aqueous humor was 2.5 hours. The concentration 
24 hours after administration was #0.2 µg/L.62 After one drop 
in each eye, the maximum plasma concentration of the free 
acid was 10−10 M and the plasma half-life was 17 minutes. 
Latanoprost undergoes extensive first-pass metabolism in the 
liver via β-oxidation to its (1, 2)-dinor and (1, 2, 3, 4)-tetranor 
metabolites, then is eliminated by urine (87.9%) and feces 
(15.3%).62
After one drop of travoprost 0.004% (1.2 µg of drug) in 
each eye, the maximum plasma concentration of the free acid 
was 10−10 M and the plasma half-life 45 minutes (Travatan 
product information, Alcon).7 The free acid is metabolized 
to inactive metabolites via β-oxidation of the α-chain to 
yield the 1, 2 dinor and 1, 2, 3, 4, tetranor metabolites, via 
  oxidation of the 15-hydroxyl moiety, as well as via reduction 
of the 13, 14 double bond. Less than 2% of the topical ocular 
dose of travoprost was excreted in the urine within 4 hours 
as the travoprost acid.7
After one drop of bimatoprost 0.03% in each eye (9 µg 
of drug), the maximum plasma concentration of bimatoprost 
amide was approximately 10−10 M (Lumigan product info, 
Allergan), peaked within 10 minutes of dosing and fell 
below the lower limit of detection within 1.5 hours.5 Mean 
maximum blood concentration and area under the curve 
values were similar on days 7 and 14 at 0.08 ng/mL and 
0.09 ng/h/mL respectively, indicating steady state levels after 
one week of ocular dosing.5 It is likely that bimatoprost enters 
the eye via the sclera as corneal tissue lacks specific amidases 
to form the active acid hydrolysis product.10 Bimatoprost 
levels were 10- to 100- times higher in the ciliary body and 
iris compared with aqueous humor. Bimatoprost undergoes 
oxidation, n-de-ethylation, and glucuronidation to form a 
diverse variety of metabolites. No drug accumulation occurs. 
Up to 67% of the administered dose was excreted in the urine 
whereas 25% was recovered in the feces.7
Clinical efficacy and differential 
impact
Studies of PGA therapy vary by way of randomization, 
masking, drug cross-over, patient selection, medication 
run-in and wash-out periods, and sponsorship. IOP measure-
ment can be diurnal (usually mean of 3 daily measurements Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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taken between 0800 and 1800 hours), investigated over a 
12-63,64 or 24-46,65,66 hour period, and/or measured at specific 
time points (peak or trough).64,67,68 The primary endpoint 
in most trials is the mean reduction in IOP from baseline. 
Because of the large number of clinical studies of variable 
scientific quality evaluating latanoprost 0.005%, bimato-
prost 0.3% and travoprost 0.004% as mono-, concomitant 
or combination therapy for OH and OAG,63,64,68–83 selected 
randomized control trials and meta-analyses will be dis-
cussed in this review. Meta-analyses may be preferable in 
evaluating drug effectiveness.84 However, meta-analyses 
are unable to fully overcome heterogeneity of partici-
pant characteristics and IOP measurement time-points, 
and may be subject to publication bias with inclusion of 
unpublished data and often exclusion of non-English trials 
or lack of notating industry-sponsored trials. Quality of a 
meta-analysis depends on the quality of trials included. 
Selected meta-analyses involving PGAs as monotherapy 
are outlined in Table 1.
Selected multicenter, single- or double-blind,   randomized 
control trials of greater than 1-month duration comparing 
the efficacy of prostaglandin analogues in OH and OAG 
are shown in Table 2. The studies used various end-point 
parameters including mean IOP reduction, %IOP reduc-
tion (%IOPR) from baseline, or target IOP levels. Baseline 
demographic parameters were similar among groups within 
each study. Mean IOP reduction was similar for latanoprost, 
bimatoprost, and travoprost and documented at 8.6 mmHg, 
8.7 mmHg, and 8.0 mmHg respectively for one study.85 
Four studies favored bimatoprost over latanoprost for 
IOP lowering.63,64,78,86 This was significant for 2 of the 4 stud-
ies. One of these studies found a significant difference only 
at 1200 and 1600 hours time-points,64 but the other study 
found a difference in IOP reduction between bimatoprost and 
latanoprost of 1.2 to 2.2 mmHg at all measured time-points 
(0800, 1200, 1600 hours).86 Bimatoprost achieved target 
IOP # 13 mmHg64,86 or #15 mmHg78 significantly more with 
than latanoprost. Bimatoprost also showed superiority over 
travoprost, but was significant only at the 0900 time-point; 
%IOP reduction from baseline for bimatoprost and travo-
prost was 27.9% and 23.3% respectively (P = 0.014).87 
Travoprost was superior to latanoprost in another study; 
mean IOP was 0.8 mmHg lower for travoprost vs latano-
prost (P = 0.0191) and final IOP of #17 mmHg or $30% 
IOP reduction was 54.7% and 49.6% for travoprost and 
latanoprost respectively (P = 0.0430).68
Several meta-analyses88–91 have directly compared 
the clinical efficacy of the three main PGAs, latanoprost, 
  travoprost, and bimatoprost. Two independent meta-analyses, 
one88 of 863,64,68,78,85–87,92 and the other89 of 13 trials (includ-
ing double-blind parallel57,63,93 or cross-over studies41,42 and 
single blind parallel64,78,85,86,94–96 or cross-over studies)97 
found bimatoprost was superior to latanoprost in lowering 
morning IOP at all time points, supported by a later post-
hoc meta-analysis of 2 independent trials with 6 months 
follow-up. Weighted mean difference (WMD) for %IOP 
reduction (%IOPR) was 2.59% (P = 0.004) at 1 month to 
5.60% (P , 0.001) at 6 months for one meta-analysis89 and 
weighted mean (WM) IOP change from baseline ranged 
from a minimum of 0.50 mmHg (P = 0.05) at 0800 hours to 
a maximum of 1.17 mmHg (P , 0.001) at 1200 hours in the 
other meta-analysis88 favoring bimatoprost over latanoprost. 
Bimatoprost was superior in IOP lowering to travoprost only 
during the daytime (0800 and 1200 hours time-points), but 
latanoprost and travoprost were comparable at all time points 
(P # 0.82).88
An industry-sponsored meta-analysis90 of travoprost vs 
latanoprost (15 trials, n = 1098),57,68,85,93,95,96,98–100 travoprost 
vs bimatoprost (8 trials, n = 714),57,85,87,93,95,96,101,102 and latano-
prost vs bimatoprost (8 trials, n = 943)57,64,85,86,93,95,96,103 found 
similar efficacy among the three PGAs. Studies comparing 
the PGA to other non-PGA glaucoma treatments, non-
randomized, dose-finding or cross-over trials, and short-term 
evaluations (less than 3 months) were excluded, although 
a trial evaluating timolol plus travoprost versus timolol 
alone,100 was included indicating that the PGA effect has the 
same relative effect as if it were compared with no treatment. 
Another industry-sponsored meta-analysis by Denis et al91 
of 9 randomized trials63,68,78,85,86,92,93,101,104 (n = 1318) found 
adjusted IOP was similar for bimatoprost and travoprost, but 
more favorable than latanoprost treated subjects. Authors 
commented that 4 trials evaluating latanoprost vs timolol, 
were not included which may have lead to a lower IOP 
decrease for latanoprost compared with the meta-analysis 
by van der Valk.84
Four trials comparing latanoprost with unoprostone 
0.15% twice daily for 1–2 months demonstrated superiority 
with latanoprost.74,79,80,82 The mean IOP reduction was approx-
imately twice as great with latanoprost as with unoprostone 
(P , 0.001), and 6–8 times as many latanoprost recipients 
achieved an IOP reduction $30% (44 and 45% vs 6 and 8%; 
P values not reported) in the two largest trials.80,82
In summary, bimatoprost appears to have superior IOP 
lowering effects over travoprost or latanoprost,63,64,78,86,88,89 
with the ability to achieve lower target IOP,64,78,86 although 
not consistently found.85,90,91,105Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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vs timolol
Before the introduction of travoprost and bimatoprost,   initial 
studies compared latanoprost 0.005% with other ocular 
hypotensives, in particular timolol 0.5%. Table 3 shows the 
characteristics and results of double-blind randomized con-
trolled trials comparing PGAs with timolol 0.5% twice daily 
for POAG and OH.
Four of these studies71–73,81 evaluated latanoprost 
0.005% and timolol 0.5% use in OH and POAG. Latano-
prost reduced mean baseline diurnal IOP by 6.2 to 
8.6 mmHg (26.8% to 35%) significantly more than timolol 
(4.4 to 8.3 mmHg (19.9% to 32.7%)) over 381 or 6 months 
of treatment,71,73 except for the study by Watson et al72 
which showed equivalence. Pooled analyses of 3 Phase 
III   studies71–73 showed a mean diurnal IOP reduction of 
7.7 mmHg (31%) for latanoprost vs 6.5 mmHg (26%) 
for timolol after 6 months, a significant difference of 
1.2 mmHg (18%), P , 0.001106 and no evidence of drift.107 
Higher baseline diurnal IOP resulted in a larger diurnal 
reduction during treatment with both drugs (P , 0.001). 
A further decrease in morning IOP of 0.7 mmHg (9%, 
P , 0.001) at 6 weeks from the initial morning IOP reduc-
tion obtained at 2 weeks was found with latanoprost,106 
which was maintained throughout 2 years of treatment,108 
supported also by the 1- and 2-year extension trials of the 
Phase III studies.109–112 The adjusted risk of IOP treatment 
failure was 8% overall,106 3.6 and 6.1 times significantly 
higher in the patients with a baseline untreated IOP of 
26–29 and 30–45 mmHg respectively. Pooling 8 studies,113 
the greatest difference in IOP lowering effect was observed 
with latanoprost in Mexican and Asian clinical trials. 
A prospective unmasked study (n = 76)114 found latanoprost 
reduced IOP from 26.5 ± 6.6 mmHg to 17.4 ± 2.7 at 3 years 
in timolol unresponsive eyes.
An independent meta-analysis115 of 11 randomized head-
to-head trials56,61,71–73,81,116–120 (n = 1256) comparing timolol 
with latanoprost documented mean (SE) percentage IOP 
reductions (%IOPR) from baseline of 31.2% (2.3) and 26.9% 
(3.4) for latanoprost and timolol respectively at 3 months, a 
significant difference in reduction of 5.0% (95% confidence 
interval [CI] 2.8, 7.3), P = 0.00, and a similar difference at 
6 months.115
The International Travoprost Study Group121 (see 
Table 3) found travoprost 0.004% reduced mean diurnal 
IOP by 8.0 to 8.9 mmHg, significantly more than timolol 
(6.3 to 7.9 mmHg), P # 0.001. Based on intent-to-treat 
data, the Travoprost Study Group122 also found a statisti-
cally significant mean IOP change from baseline for travo-
prost 0.004% (−6.5 to −7.1 mmHg) than for timolol 0.5% 
twice daily (−5.2 to −6.8 mmHg). Higginbotham et al123 
Table 3 Characteristics of double-blind randomized control trials of 1 to 9 months’ duration comparing prostaglandin analogs with 
timolol 0.5% twice daily for ocular hypertension and open-angle glaucoma
Author/year/ 
location
Design Randomized  
PGA
Duration  
(months) 
N Mean age (yrs)/ 
%female/%  
withdrawal
No. of OAG/ 
OH/Othera
% diurnal IOP  
reduction from  
baseline
P-value
PGA Timolol
Alm71/1995/ 
Scandb
DB-P 
DB-C
Lat mane or  
nocte
6 267 67/56.6/6 91/123/53 35 (nocte) 
31 (mane) 
27 P = 0.001
Camras73/1996/ 
USAb
DB-P Lat nocte 6 268 62/57.5/7 84/170/14 27 20 P = 0.001
watson72/1996/ 
UKb
DB-P Lat nocte 6 294 65/35.0/9 121/148/25 33.7 32.7 NS
Mishima81/1996/ 
Japan 
DB-P Lat mane 3 178 57/51.1/11 NR 26.8 19.9 P , 0.001
Brandt124/2001/ 
USAb 
DB-P Bim nocte or  
bd
3 596 62/56.0/7.4 373/218/5 35.2 (nocte) 
30.4 (bd)
26.2 P , 0.001
whitcup125/2003/ 
USAb
DB-P Bim nocte or  
bd
3 602 61/53.7/8.6 300/284/18 32.4 (nocte) 
25.2 (bd) 
22.7 P , 0.001
Goldberg121/2001/ 
variousb 
DB-P Trav nocte 9 382 63/49.7/3.1 208/147/27 30.8–31.6 25.1–27.9 P # 0.0001
Fellman122/2002/ 
USAb
DB-P Trav nocte 6 396 NR/52.5/2.8 251/132/13 From pooled visits, Trav  
was superior to Tim 
P , 0.0130
Abbreviations: bd, twice daily; Bim, bimatoprost 0.03%; DB-C, double-blind, cross-over; DB-P, double-blind, parallel; Lat, latanoprost 0.005%; mane, every morning; nocte, 
every night; NR, not recorded; NS, not significant; OH, ocular hypertension; OAG, open-angle glaucoma; PGA, prostaglandin analog; Scand, Scandinavia; Trav, travoprost 
0.004%; wks, weeks; Tim, timolol.
aincludes pseudoexfoliative, pigment dispersion and other secondary glaucomas; bindicates sponsorship by Pharmacia inc.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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pooled 1-year results from the Bimatoprost Study Groups 
1124 and 2125 (n = 1198) found bimatoprost 0.03% once daily 
was more efficacious than bimatoprost 0.03% or timolol 
0.5% twice daily.123 An IOP # 17 mmHg was achieved 
in 58% of bimatoprost once daily patients compared with 
37% of timolol treated subjects. Bimatoprost lowered IOP 
to the same extent in blacks and non-blacks, while timolol 
was less effective in blacks (by approximately 2 mm). Mean 
reduction with bimatoprost 0.03% once daily was sustained 
over 2126 and 4127 years, and remained lower than timolol 
(P # 0.001).
Holmstrom et al128 analyzed efficacy of latanoprost 
(33 studies), bimatoprost (18 studies) and travoprost 
(8 studies) monotherapy, and combined latanoprost/timolol 
(11 studies), bimatoprost/brimonidine (1 study), and 
  travoprost/timolol (2 studies). Difference in %IOPR was 
6%; IOPR% was 27.2% for PGA use (collectively)63,64,67,68, 
71–73,78,80–82,85,86,92,116,117,119,121,122,124,125,129–143 compared with 21.2% 
for timolol67,68,71–73,78,81,116,117,119,121,122,124–126,131,134,135,137,139,142,143 
with 0- to 1-month data, and 22.2% and 28.6% for timolol 
and PGA respectively for studies with 0- to 6-months data. 
Pooling all data128 the WM %IOPR was 30.3%, 28.7%, 
and 26.7% for bimatoprost, travoprost, and latanoprost 
respectively. Latanoprost studies had a lower baseline IOP 
(WM baseline IOP 24.84 mmHg) compared with bimato-
prost (25.74 mmHg) or travoprost (26.83 mmHg), possibly 
due to a larger percentage of patients with run-in timolol 
treatment (16%, 5% and 0% for latanoprost, bimatoprost 
and travoprost respectively). Another meta-analysis105 found 
travoprost 0.004% was equivalent in lowering IOP compared 
with bimatoprost 0.03%85,86,92,93,95 (WMD = 0.08, P = 0.8) or 
latanoprost 0.005%68,85,93,95,98,104 (WMD = −0.57, P = 0.07), 
but superior to timolol.68,121,122,144
In summary, the vast majority of studies support IOP-
lowering superiority of latanoprost,71,73,81,106 travoprost,121,122 
and bimatoprost,124,125,137 over timolol, and although not 
entirely consistent.72 PGAs were effective in eyes unrespon-
sive or inadequately controlled with timolol, and remained 
effective long term.
vs brimonidine
Two meta-analyses145,146 comparing efficacy of   latanoprost 
and brimonidine both favored latanoprost for IOP 
  lowering.145 In one meta-analysis,145 the estimated   absolute 
decrease in IOP from baseline for latanoprost and brimo-
nidine was respectively −8.4 and −6.5 mmHg at 3 months 
(P = 0.004) and −8.0 and −6.2 mmHg at 6 months 
(P = 0.045).   Head-to-head trials post-dated the study 
hence studies comparing the medication in question and 
timolol71–73, 81,116,119,147,148 or betaxolol149 were included. In 
contrast, head-to-head trials,43,52,53,59,70,76,77,83,150–157 only were 
analyzed for the second meta-analysis.146 The pooled sum-
mary estimate significantly favored latanoprost (weighted 
mean difference (WMD) = 1.10, 95% CI 0.57 to 1.63) 
over brimonidine. A third meta-analysis158 did not find a 
significant reduction in mean IOP when latanoprost was 
compared with brimonidine (WMD = −1.04; P = 0.30). 
This pooled result did not change when only two higher-
quality studies70,76 were analyzed; one study part funded 
by Pharmacia70 favored latanoprost (adjusted mean diurnal 
IOP reduction = 5.7 mmHg) over brimonidine (3.1 mmHg) 
and the other study supported by Allergan76 did not find a 
significant difference between treatments; mean %IOPR 
was 27.8% vs 27.0% for latanoprost and brimonidine 
respectively. Clinical success (based on IOP lowering 
efficacy, tolerability and patient satisfaction) at 3 months 
was greater with the brimonidine group (91% vs 74%, 
P = 0.01),76 although the former study70 experienced 5 times 
more adverse effects from brimonidine use. In summary, 2 
of 3 meta-analyses found improved efficacy of latanoprost 
than brimonidine in IOP lowering.
vs dorzolamide
Hodge et al158 also compared latanoprost with dorzolamide 
through a meta-analysis of 3 studies75,159,160 (n = 328). Mean 
IOP was lower in the latanoprost compared with the dorzo-
lamide group (WMD = −2.64 mmHg; P , 0.00001). The 
largest of the studies analyzed75 documented a significant 
lowering of diurnal IOP with latanoprost (8.5 mmHg) than 
dorzolamide (5.6 mmHg; P , 0.001).75
Rank order of ocular hypotensives as monotherapy
Pooled one-month IOP-lowering effect from baseline to 
peak (n = 6953) and trough (n = 6841) of 8 commonly used 
ocular hypotensives was reported by van der Valk et al.84 
At peak, greatest %IOPR was achieved by bimatoprost 
(33%), followed by latanoprost (31%), travoprost (31%), 
timolol (27%), brimonidine (25%), betaxolol (23%), dorzo-
lamide (22%), brinzolamide (17%), and a placebo (5%). At 
trough, greatest%IOPR was achieved by travoprost (29%), 
followed by bimatoprost (28%), latanoprost (28%), timolol 
(26%), betaxolol (20%), brimonidine (18%), brinzolamide 
(17%), and dorzolamide (17%). A network meta-analysis 
also by van der Valk161 found mean IOP reduction at peak 
was greatest with bimatoprost, travoprost and latanoprost, 
followed by other ocular hypotensive agents, and at trough Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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bimatoprost, latanoprost, and travoprost followed by other 
ocular hypotensive agents.
Stewart et al162 evaluated studies of ocular hypotensive 
therapy efficacy measured over 24 hours. Greatest 24-hour 
IOP reduction was found with bimatoprost (29%) and 
travoprost (27%) than latanoprost (24%), combination dor-
zolamide and timolol (19%), or brimonidine (14%). Mean 
reduction of night-time points was statistically lower than 
that of day time points for latanoprost (P = 0.031), timolol 
(P = 0.032), and brimonidine (P = 0.050) but not for dorzo-
lamide (P = 0.60), bimatoprost (P = 0.057) and travoprost 
(P = 0.064). Latanoprost showed greater 24-hour efficacy 
with night dosing (24%) than morning dosing (18%). For 
travoprost, there was no a significant difference between 
night (27%) or morning (26%) dosing (P = 0.074).
Twenty-four-hour IOP measurements may provide 
better information for clinical decision-making than 
daytime IOPs alone.162 Higher peak pressure163,164 may be 
an independent risk factor for glaucomatous progression 
and IOP measurements outside normal office hours can 
change the peak pressure assessment in 69% to 75% of 
cases.165,166 In other studies, mean reductions in IOP were 
lower with latanoprost than with timolol 0.5% during 
both the daytime and night-time hours (P # 0.05)46,66 as 
timolol did not reduce IOP as much at night (P = 0.04).66 
Flattening of the 24-hour IOP curve, thus reduction in IOP 
fluctuations was documented for bimatoprost63,143,163 and 
latanoprost,168 importantly for NTG subjects in the lat-
ter. The 24-hour diurnal IOP was statistically lower with 
bimatoprost compared with latanoprost in a double-masked 
cross-over comparison (n = 42), although the difference 
was small and latanoprost better tolerated with regard to 
conjunctival hyperemia.41
However, for NTG a meta-analysis169 found IOP reduc-
tion was greatest for brimonidine (24%), followed by 
bimatoprost (21%), latanoprost (20%), timolol (15%), and 
dorzolamide (14%) at peak, and greatest for latanoprost 
(20%), followed by timolol (18%) and bimatoprost (18%), 
dorzolamide (12%), and brimonidine (11%) at trough. Ten 
of the 15 trials involved a PGA.44,53,56,103,114,169,170–173
Subjects (n = 1571) switched to latanoprost from previous 
glaucoma monotherapy and fixed and unfixed combination 
therapies maintained IOP to an acceptable level through a 
2-year period.174 Latanoprost-insensitive patients developed 
IOP lowering with bimatoprost in a randomized prospective 
study with two 30-day treatment phase and 30-day wash-
out phase.136 IOP on bimatoprost (18.1 ± 1.7 mmHg) was 
significantly lower than either baseline (24.8 ± 1.1 mmHg, 
P , 0.0001) or latanoprost (24.1 ± 0.9 mmHg, P = 00001) 
when rechallenged.
In summary, all three PGAs have documented superior-
ity over other ocular hypotensives in various meta-analyses 
with respect to %IOPR84 and 24-hour IOP reduction for OH 
and POAG.162  %IOPR may be superior for brimonidine than 
PGA for NTG.169 PGAs are as effective for IOP-lowering at 
night-time as for day-time.
Adjunctive therapy
In timolol-treated subjects, adjunctive latanoprost   lowered 
IOP significantly more than adjunctive dorzolamide 
(−7.06 mmHg; 32% vs −4.44 mmHg; 20% for adjunctive 
latanoprost and dorzolamide respectively) after 3-months in 
one study175 and more than adjunctive pilocarpine 2%, 3 times 
daily in another.130,176,177 Addition of latanoprost to pilocarpine 
therapy does not appear to diminish uveoscleral outflow178,179 
but is instead additive,178,180–183 contrary to thoughts that cili-
ary muscle contraction with cholinergics hinders uveoscleral 
outflow.179 In subjects (n = 115) with uncontrolled IOP on 
β-blocker monotherapy, adjunctive latanoprost (23.5%) or 
brimonidine (22.8%) were comparable in%IOPR at peak 
effect at one month, but brimonidine was better tolerated than 
latanoprost.151 As third-line agents, overall mean%IOPR was 
not significantly different between brimonidine (22.8%) and 
latanoprost (17.2%), although brimonidine (85%) had slightly 
higher although non-significant clinical success ($15% 
reduction in IOP from baseline) than latanoprost (65%).152
An additive effect of latanoprost was seen in an open-
label 1-week trial of subjects with uncontrolled IOP on 
concomitant timolol and dorzolamide twice daily184 with 
an additional 16% reduction in IOP, and a 3-month study 
of subjects with uncontrolled IOP on fixed combination 
dorzolamide/timolol (FCDT) with a further 5.2 mmHg IOP 
reduction at peak and 3.5 mmHg at trough.150 A retrospective 
analysis of 73 eyes with uncontrolled IOP on latanoprost 
documented better %IOPR with adjunctive dorzolamide 
(19.7%, P , 0.001) than β-blockers (12.3%, P , 0.001) or 
brimonidine (9.3%, P = 0.0011).185
vs dual therapy
A meta-analysis186 of 14 studies43,50,60,99,133,187–195 (n = 2149) 
found latanoprost lowered diurnal mean IOP significantly 
more than concomitant dorzolamide/timolol (11/14 studies 
used FCDT) if subjects were uncontrolled on timolol mono-
therapy (WMD for mean %IOPR was 3.12 (95% CI, 0.47 to 
5.78), but was of equal efficacy if no baseline timolol was 
given. Post-hoc analyses196 from 2 randomized, multicenter, Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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double-masked trials133 comparing latanoprost with FCDT 
independent of baseline timolol use found equal efficacy 
for mean IOP at each time-point, mean IOP reduction for 
high IOP at baseline, and 40% IOP reduction. FCDT and 
latanoprost have similar 24-hour IOP-lowering efficacy after 
2-months, but latanoprost further reduced mean 24-hour IOP 
by 0.3 mmHg (P = 0.01) at 6 months.195
Bimatoprost decreased IOP from baseline by 6.8 to 
7.6 mmHg, significantly more than FCDT (4.4 to 5.0 mmHg, 
P , 0.001) in a randomized 3-month double-masked trial 
of subjects (n = 177) inadequately controlled with timolol132 
Subjects achieving IOP s of #13, #14, #15, #16 mmHg 
were more than twice as high for bimatoprost than for 
FCDT (all P # 0.008). Similar efficacy was found between 
bimatoprost 0.03% and concomitant timolol and latano-
prost in a randomized 6 month investigator masked study 
of 56 subjects with a timolol run-in.140 To date, there are no 
published studies evaluating the efficacy of fixed or unfixed 
combinations of brimonidine/timolol with latanoprost, tra-
voprost or bimatoprost.
PGA/timolol fixed combinations
Diurnal IOP levels were lower with fixed   combination 
latanoprost 0.005%/timolol 0.5% (FCLT) solution (Xala-
com®; Pfizer Inc., NY, NY) (19.9 ± 3.4 mmHg), com-
pared with timolol (23.4 ± 5.4 mmHg) and latanoprost 
(20.8 ± 4.6 mmHg) monotherapy in a 6-month double-
masked trial (n = 418).137 The mean 24-hour diurnal curve was 
19.2 ± 2.6 mmHg for latanoprost alone vs 16.7 ± 2.1 mmHg 
for FCLT in another trial.197 A meta-analysis of randomized 
clinical trials of 1 to 3 months’ duration198 documented 
greater pooled IOP change from baseline with concomi-
tant latanoprost and timolol (−6.0 mmHg),67,130,176 than 
FCLT (−3.0 mmHg),137,142 concomitant dorzolamide and 
timolol (−4.1 mmHg at trough and −4.9 mmHg at peak), 
or FCDT (−3.8 mmHg at trough and −4.9 mmHg at peak). 
Omission of the evening timolol dose with FCLT possibly 
explains the large difference in IOP between fixed and con-
comitant use. Studies evaluating add-on therapy pre-selects 
patients with higher untreated IOP or those unresponsive to 
timolol. Only one study reported the pre-run-in IOP.198 No 
measurement of expected peak latanoprost effect was made 
for studies on FCLT, whereas at least 1 measurement at 
the expected peak latanoprost effect for studies evaluating 
concomitant treatment was done.198 Subjects (n = 325) with 
inadequate IOP control (IOP . 16 mmHg) on mono- or dual 
therapy had lower diurnal IOP with FCLT (16.9 mmHg) 
than concomitant brimonidine and timolol (18.2 mmHg), 
P , 0.001, at 6 months,156 also supported by a cross-over 
study with a 1-month timolol run-in period.154
Data from 3 Phase III clinical studies199,200 have shown 
that the fixed combination of bimatoprost 0.03%/timolol 
0.5% (FCBT) ophthalmic solution (Ganfort®; Allergan inc., 
Irvine, CA) was significantly more effective in lowering 
IOP, with a higher percentage achieving mean reduction in 
diurnal IOP of .20% or a target pressure of ,18 mmHg, 
than timolol or bimatoprost monotherapy. From the pooled 
analysis of 2 trials,199 mean reduction in IOP from baseline 
was 7.4 to 9.6 mmHg in the FCBT group, 6.7 to 8.8 mmHg 
in the bimatoprost group, and 5.2 to 7.4 mmHg in the timolol 
treated group. Some subjects were unresponsive to timolol 
prior to the study and one study had a run-in period of 
timolol twice daily. FCBT was non-inferior to concomitant 
administration of its component parts in a randomized, double 
blind, 3-week study of patients with OAG or OH naïve to 
treatment.201 Mean diurnal IOP was 16.1 mmHg with FCBT, 
15.6 mmHg with concomitant bimatoprost and timolol, and 
17.1 mmHg with bimatoprost monotherapy.201 Two random-
ized, parallel group 4-202 and 12-week203 studies found FCBT 
was superior to FCLT in reducing mean diurnal IOP versus 
baseline at each time point. In the 12-week study,203 more 
subjects had a mean IOP reduction from baseline of $20% 
with FCBT than FCLT (61.7% vs 17.1%). Subjects in both 
studies were insufficiently controlled on PGA, and there was 
no wash-out period.
Fixed combination travoprost 0.004%/timolol 0.5% 
(FCTT) ophthalmic solution (Duotrav®; Alcon Inc., Fort 
Worth, TX) lowered IOP 1.9 to 3.3 mmHg more than 
timolol alone and 0.9–2.4 mmHg more than travoprost 
alone.144 Adverse events rates were comparable. FCTT low-
ered absolute IOP level (2.4 mmHg) for the 24-hour curve 
and at all time points, compared with travoprost (P # 0.047), 
and the mean 24-hour IOP fluctuation was lower with 
FCTT (3.0 mmHg) compared with travoprost (4.0 mmHg, 
P = 0.001).204 FCTT had similar efficacy to concomitant 
travoprost and timolol.205 Mean differences between FCTT 
and concomitant treatment was ±0.4 to ±1.1 mmHg. Per-
cent IOP reduction from baseline was 29.1% to 33.2% for 
combination, 31.5% to 34.8% for concomitant, and 19.3% 
to 27.0% for timolol therapy alone.205 These findings are 
also supported by a 3-month study of 316 patients.206 FCTT 
did not demonstrate significant differences in mean IOP or 
mean IOP change from baseline compared with concomi-
tant latanoprost and timolol in 2 studies.207,208 A 12-month 
randomized control, parallel-group trial showed statistically 
equal or better mean IOP for FCTT (16.4 to 17.1 mmHg) than Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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FCLT (16.7 to 17.7 mmHg),100 supported by a   retrospective, 
cross-sectional study.210 However, ocular hyperemia rates 
were higher with FCTT (15%) compared with FCLT 
(2.5%).100 Compared with FCDT, mean pooled diurnal IOP 
was significantly lower with FCTT (16.5 ± 0.23 mmHg vs 
17.3 ± 0.23 mmHg; P = 0.011) in a randomized-control, 
parallel, double-masked trial (n = 319).209 FCTT produced 
mean IOP reductions of 35.3% to 38.5%, FCDT reduced IOP 
32.5% to 34.5%. There do not appear to be studies directly 
comparing FCTT with FCBT.
In summary, fixed combinations of PGA with timolol are 
superior to monotherapy with its constituent parts.137,144,199 
Non-inferiority compared with the unfixed combina-
tion was found for FCBT201 and FCTT,205 though not for 
FCLT.198 FCBT and FCTT appear to be more efficacious 
than FCLT.
Adverse effects
Table 4 shows differential rates of adverse events among the 
3 main PGAs as reported in the randomized control trials 
summarized in Table 2.
Ocular adverse events
Conjunctival hyperemia
Conjunctival hyperemia was the most common adverse 
effect from PGAs observed in several studies.64,78,85–87,123 All 
studies outlined in Table 4 show significantly higher rates of 
ocular hyperemia with bimatoprost and travoprost compared 
with latanoprost, except one.63 Travoprost and bimatoprost 
have similar rates.87,211 A meta-analysis of 13 randomized 
control trials found reduced rates of ocular hyperemia in 
subjects using latanoprost than both travoprost (odds ratio 
[OR] = 0.51; 95% CI 0.39 to 0.67, P , 0.0001) or bimatoprost 
(OR = 0.32; 95% CI 0.24 to 0.42, P , 0.0001).211 Ocular 
hyperemia rates of 49.5% for travoprost, 27.6% for latano-
prost, and 14% for timolol 0.5% have also been reported.17
Hyperemia was generally mild in severity, began within 
2 days after starting PGA and diminished around 2 to 4 weeks, 
although may persist over time.85,123 Discontinuation rates 
due to hyperemia were 3.4% for bimatoprost daily (5.6% for 
twice daily dosing), and 0.4% for timolol. Variability in the 
occurrence of hyperemia among those treated with PGAs may 
reflect a chemical difference in their molecular structure.213 
Table 4 Differential adverse event rates among prostaglandin analogs as reported in multi-center, randomized control trials summarized 
in Table 2
First author/year N Reported rates of adverse events
Ocular Systemic
Parrish85/2003  410 CH: Bim 68.6%, Trav 58.0%, Lat 47.1%, P = 0.001 Bim vs Lat 
Moderate CH: Bim 15.3%, Trav 10.1%, Lat 5.9% 
eye irritation: Bim 10.9%, Trav 4.3%, Lat 6.6% 
eyelash growth: Bim 2.9%, Trav 0.7%, Lat 0% 
Skin discoloration: Bim 2.9%, Trav 2.9%, Lat 1.5%
Bim 18.2%, Trav 16.7%, Lat 16.9%. events  
reported .2% were nasopharyngitis, 
upper respiratory tract infection, 
headache 
DuBiner63/2001  43 CH: Bim 14.3%, Lat 14.3%
Gandolfi64/2001  232 CH: Bim 36.1%, Lat 14.2%, P # 0.001. Mild 
eyelash growth: Bim 12.6%, Lat 4.4%, P = 0.026 
Ant uveitis: 1 subject each 
No CMe or iris change
Headache: 4.4% Lat vs 0% Bim, P = 0.026
Noecker86/2003  269 CH (slit-lamp): Bim 55.4%, Lat 42.5%, P , 0.001 
eyelash growth: Bim . Lat, P = 0.064 
iris change: 1 subject Bim 
Ant uveitis: 1 subject Lat 
No CMe
12 serious adverse events. None reported 
to be related to study medication
walters78/2004 76 CH: Bim 39.5%, Lat 15.8%, P = 0.021. Mild 14/15 cases 
eye pruritis: Bim 13.2%, Lat 2.6%, P = 0.20 
Ant uveitis: 1 subject Lat 
No CMe
–
Netland68/2001  390 CH: Trav 38.0%, Lat 27.6%, mainly mild 
eyelash growth: Trav 57.1%, Lat 25.8% 
iris change: Trav 3.1%, lat 5.2% 
No anterior uveitis, No CMe
–
Cantor87/2006 157 CH: Bim 21.1%, Trav 14.8%, P = 0.326 
Ocular itching: Bim 2.3%, Trav 7.4%, P = 0.278 
iris change: 1 subject Bim
–
Abbreviations: Ant, anterior; Bim, bimatoprost 0.03%; CH, conjunctival hyperemia; CMe, cystoid macular edema; Lat, latanoprost 0.005%; Trav, travoprost 0.004%.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Phenyl-substituted analogs significantly reduced the   surface 
hyperemic effect of PGF2α – isopropyl ester, based on 
reduced co-stimulation of the vasodilatory EP prostanoid 
receptors, although other mechanisms involving both sensory 
nerves and a release of nitric oxide (NO) are at play.22
iris pigmentation
Iris darkening is a recognized, common, and significant ocular 
side effect of PGAs,73,111,214 and changes appear to be irrevers-
ible or very slowly reversible.215,216 Latanoprost-induced iris 
hyperpigmentation after 1 year was noted in 12%, 23%, and 
11% of patients in the USA, UK, and Scandinavia, respec-
tively, mostly in mixed-color eyes (green-brown, yellow-
brown, and blue/grey brown).68 Iris pigmentation change was 
lower in travoprost 0.004% (3.1%) than latanoprost (5.2%).68 
A third of subjects with hazel irides developed recognizable 
iris darkening by 5 years.215 A high 12-month incidence of 
42.8%217 to 58.2%218 of iris darkening in brown irides in 
Japan214,216 and Taiwan217 has been documented. Homoge-
neous blue, green, or grey eyes are rarely affected.214,216 Iris 
pigmentation may appear as soon as 3 months after initiation, 
develop in most (75%) affected subjects within 7 months,217 
and stabilize from 12126 to 36 months.215
Increased iris hyperpigmentation is likely to be related to 
PGA-stimulated increase melanogenesis,22,219–222 and possible 
increase in iris stromal melanocyte numbers223 or their migra-
tion to the anterior border region with no net gain in melanin 
or melanocyte numbers.224 Latanoprost-exposed iridectomy 
specimens showed increased melanin within the stromal 
melanocytes, but no evidence of pre-malignant change.225 
Tissue culture226,227 and light microscopy216 experiments do 
not show division and replication of iris stromal melanocytes. 
In vitro increase in PGE2 by latanoprost also suggests its role 
as an intracellular signaling agent to promote gene transcrip-
tion and melanogenesis.22 Potential problems with excess 
melanin include melanin granule release and inflammatory 
response in the stroma, melanin-induced anterior uveitis, or 
secondary pigment-induced glaucoma.228
Hypertrichosis
Reported increase in length, number, color and thickness 
of eyelashes,229,230 from all PGAs,64 can affect between 45% 
and 57% of subjects after 6 to 12 months’ treatment,229,231 
and interfere with drop instillation.232 Also, additional lash 
rows, conversion of vellus to terminal hairs in canthal areas 
and regions adjacent to lash rows,233 lash ptosis, trichiasis, 
reversal of alopecia and poliosis can occur.234,235 Random-
ized studies over 3 months found over 3-fold increase with 
bimatoprost compared with latanoprost.64,85 The increased 
number of lashes is consistent with the ability of the PGA 
to induce anagen (the growth phase) in telogen (resting) 
  follicles while inducing hypertrophic changes in the involved 
follicles. The increased lash length is consistent with the 
ability of the PGA to prolong the anagen phase of the hair 
cycle. Initiation and completion of PGA induced hair growth 
effects occur very early in anagen and the likely target is the 
dermal papilla.233
Periocular skin pigmentation
Darkening of the skin of the lids or other sites around the 
eye has been reported as a side effect associated with PGA 
use,236–242 including development in black236 subjects. The 
incidence of acquired skin pigmentation was 1.5% for 
latanoprost and 2.9% for bimatoprost and travoprost in 
one trial,85 although numbers were small, and follow-up 
only 12 weeks.85 Pigmentation can develop within months, 
and possibly   earlier with bimatoprost use compared with 
  latanoprost (1 vs 3 months),236 or take even as long as 
3 years.238 Periocular pigmentation resolves without seque-
lae within 3 to 12 months for bimatoprost239 and weeks for 
latanoprost.236–238 with medication cessation. PGA-induced 
increase in melanogenesis216 and melanocyte proliferation243 
have been implicated,244 although a contact dermatitis-like 
reaction with inflammation may contribute.239,245 FP receptors 
have been localized in hair follicles.216
Cystoid macular edema
Endogenous prostaglandin release induced by anterior seg-
ment inflammation can lead to blood aqueous breakdown, 
inflammatory mediators reaching the macula, and cystoid 
macular edema (CME). Prostaglandin levels increase after cat-
aract surgery246 and CME can resolve with non-steroidal anti-
inflammatory therapy (NSAID).247,248 Laser flare cell meter 
shows latanoprost enhances breakdown of blood-  aqueous 
barrier and increase in angiographic CME after cataract 
surgery,249 although disputable.71–73,81,250 CME is reported to be 
higher in patients with posterior capsular rupture with vitreous 
loss, chronic topical medication use including   epinephrine251 
possibly due to increased prostaglandin synthesis induced 
by benzalkonium chloride (BAC),248 diabetes, and following 
laser procedures including laser capsulotomy.228 A definitive 
link between PGA and CME is, however, hard to establish, 
as eyes developing CME generally have an independent risk 
factor for CME.250 Pharmacologic considerations indicate that 
concentrations of PGA reaching the posterior segment are too 
low to induce vascular actions.250Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Anecdotal reports of CME252–255 with PGA use 
(  latanoprost, travoprost, bimatoprost or unoprostone) 
occurred in patients with CME risk factors including apha-
kia, complicated cataract surgery, ruptured PC, history of 
uveitis, and retinal inflammatory or vascular disease. One 
study found clinical CME in 2/136 eyes (1.2%), but one sub-
ject had a ruptured posterior capsule and anterior chamber 
lens and the other was pseudophakic and had active uveitis 
1 month prior to starting latanoprost.256 Another study 
found clinical CME in 3/212 (1.4%) post-cataract eyes on 
latanoprost therapy, all of whom had a ruptured posterior 
capsule requiring vitrectomy.257 In a prospective study of 
latanoprost therapy in 33 pseudophakic eyes, with ruptured 
posterior capsules, 2 (6%) had clinical CME.258 However, 
there were no cases of CME reported in Phase I and II 
latanoprost trials (about 800 subjects) and incidence was 
less than 1% in Phase III studies (about 2400 patients over 
6 months).250 A study of 605 patients (excluding subjects 
with ocular trauma or incisional eye surgery) reported no 
CME with travoprost use.122 In 163 eyes of 84 consecutive 
patients with uveitis and raised IOP, there was no increase 
in the frequency of visually significant CMO (P = 0.19) or 
anterior uveitis (P = 0.87) with PGA treatment compared 
with no PGA treatment.259
Although CME risk appears extremely low to non-  existent 
in low-risk eyes (no intraocular surgery or uveitis)260 and that 
even high risk eyes have relatively low incidence, caution 
should still be exercised during use in high risk eyes.250 CME 
is reversible with discontinuation, and   preventable with a 
NSAID without loss of effectivity.249
Anterior uveitis
Anterior uveitis is a rare potential side effect of PGA. PGF2α 
may stimulate the release of PGE2, and hence activate 
phospholipase II, enhancing the production of inflammatory 
eicosanoids.261 In support of an association between PGA 
and anterior uveitis, the inflammation appears to occur in the 
ipsilateral treated eye,261 improve after cessation and recur 
after rechallenge.256 Excessive doses may induce iritis.262 
Affected subjects may have history of prior inflammation 
and/or incisional surgery.261 A case report256 documents an 
anterior uveitis rate as high as 4.9%, although no increase was 
found in PGA-treated subjects with anterior uveitis compared 
with those not on PGA treatment.259 No increase in uveitic 
relapse rates were found when latanoprost was compared 
with FCDT (P = 0.21).263 Fluorophotometry and laser-flare 
cell meters have failed to detect an effect of latanoprost on 
aqueous flare intensity.170
Herpes simplex keratitis
Herpes simplex keratitis (HSK) associated with latanoprost 
use has been reported to recur with latanoprost rechallenge, 
be unresponsive to anti-viral therapy until latanoprost was 
stopped,264 and cause recurrent disease when inactive for 
10 years.265 HSV type 1 infected white rabbit eyes266 had an 
increased severity of active HSK within 5 days of initiating 
topical latanoprost, and a significant increase in the clinical 
recurrence of HSK, although increased doses were given, 
and lack of viral cultures could not exclude development of 
pseudo-dendrites with epithelial toxicity. Data extracted from 
the claims records of 93,869 glaucoma patients between 1996 
and 2002, showed 411 patients with ocular herpes simplex 
virus, which is a similar rate to that found in the general 
population and did not correlate with any particular anti-
glaucoma therapy.267 The risk of activating an ocular herpes 
simplex infection through the initiation of PGA is thus quite 
low, but based on anecdotal264 and laboratory reports, it is 
important to enquire about history of HSK before initiating 
therapy.
iris cyst
Reversible iris cyst formation is a rare reported complication 
of latanoprost use.268–271 Proposed mechanisms of iris cyst 
formation may be related to flow pressures on the ciliary 
muscle and intraepithelial space of the posterior iris cre-
ated by increased uveoscleral drainage269,272 in predisposed 
subjects, or influence on secretory functions of cyst epi-
thelium. Rapid reversal and lack of recurrences makes any 
  proliferative event unlikely.
Systemic adverse events
PGA related systemic adverse events occurring via nasopha-
ryngeal mucosal absorption273 are infrequently seen due to 
a relatively rapid elimination half-life. Thromboxane A2, 
PGF2 and PGE2 elicit contractile responses in isolated human 
bronchial smooth muscle with bronchial hyperresponsive-
ness and constriction, and changes in microvascular leakage 
airway smooth muscle.273 PGAs are however, relatively 
selective PGF2α receptor agonists with minimal effects on 
the thromboxane receptor.274 A randomized cross-over study 
exposing subjects with stable asthma to 6 days of latanoprost 
followed by a 2-week washout, found no significant effects 
on peak expiratory flow, asthma symptoms or requirement 
for asthma medications.273 Latanoprost for 3 months did not 
affect peak expiratory flow, forced expiratory volume in 
1 second (FEV1), and FEV1/forced ventilatory capacity in 
33 patients with newly diagnosed glaucoma.157 In a 6-month Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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clinical study, adverse respiratory events were similar 
for latanoprost (2%) and brimonidine (2%).83 However, a 
Swedish study found discontinuation of latanoprost therapy 
ameliorated deterioration of asthma in three patients with 
pre-existing asthma,275 and severe apnea occurred 30   minutes 
after administration of latanoprost in one patient, which 
disappeared within 1 hour.
Upper respiratory tract infection interestingly was the 
most common systemic adverse event from latanoprost 
observed in clinical trials and occurred at a rate of approxi-
mately 4%.276 Other systemic events included chest pain, 
muscle/joint/back pain, and rash/allergic skin reaction.276 
Angina,277 latanoprost-induced arterial hypertension and 
tachycardia,278 facial and peripheral edema, and new-onset 
migraine 64279 have been anecdotally reported. Concurrent 
use of vitamin E in 2 subjects with arterial hypertension278 
may have altered arachidonic acid metabolism, and hence 
prostaglandin quantities.278 Intravenous infusion of latano-
prost in cynomolgus monkeys at 10 times the clinical dose 
had no cardiovascular or pulmonary effects.32
Dosage and administration
PGAs are indicated for the reduction of IOP in OH and OAG. 
All PGAs are supplied as a sterile, isotonic, buffered   aqueous 
solution with their respective active ingredient (latano-
prost 0.005% [50 µg/mL], travoprost 0.004% [40 µg/mL], 
and bimatoprost 0.03% [0.3 mg/mL]) and benzalkonium 
chloride as the preservative. Travoprost has the lowest 
pH at 6.0, followed by latanoprost (6.7) and bimatoprost 
(6.8 to 7.8). A single drop of PGA once daily in the eve-
ning is the recommended dosage.276 Increased PGA dosage 
frequency24,129,143,280,281 or combined PGA therapy282 can result 
in diminished action, possibly due to desensitization at the 
level of the FP receptor.24
Efficacy of eye drops is dependent on proper storage 
and preservation. Unopened bottles of latanoprost should be 
refrigerated between 2°C and 8°C, whereas opened bottles can 
be stored at room temperatures for up to 6 weeks. Bimatoprost 
can be stored at temperatures between 15°C and 25°C, and 
travoprost between 2°C and 25°C for up to 6 weeks.281 If used 
in combination with other topical ocular hypotensive agents, 
the medications should be administered at least 5 minutes 
apart to avoid wash-out and precipitation with drops contain-
ing thimerosal.276 Contact lenses should be removed prior to 
instillation for 15 minutes.283   Polypropylene bottles are needed 
to dispense travoprost as polyethylene used for latanoprost 
and bimatoprost allow adherence of travoprost to the sides of 
the container, thus decreased concentrations.17
Contraindications include known hypersensitivity to the 
active or other ingredients, or benzalkonium chloride. Cau-
tious use in patients with intraocular inflammation (eg, iritis 
or uveitis), renal or hepatic disease (as not investigated), 
pediatric patients, pregnancy (no adequate studies), and 
nursing mothers should be exercised.
Tolerance, medication persistency 
and patient-focused perspectives
The long-term side effect profile of latanoprost has been 
studied most, but the other currently available PGAs appear 
to have a similar spectrum of side effects, supporting also 
the notion of similar mechanisms of action.12 A large 
5-year, open-label, multicenter study of latanoprost safety284 
(n = 5854), found macular edema, iritis/uveitis, or corneal 
erosion rates of #2.72% and a serious adverse drug reac-
tion (CME (n = 4), uveitis (n = 3), chest pain, eye irritation, 
headache, dermatitis due to eye drop allergy, conjunctivitis, 
dyspnea and macular degeneration (n = 1 each)) rate of 
0.44% with latanoprost use, similar to the usual care group. 
Overall discontinuation rates with latanoprost (2.46%) were 
similar to usual care (2.24%), and most frequently attributed 
to macular edema and iritis/uveitis, although unmasked 
groups could have led to a biased association.284 Discon-
tinuation from respiratory disease was more frequent in the 
usual care group (60 vs 16 patients).284 Another open-label, 
5-year study215 of adjunctive latanoprost therapy also found 
marked iris pigmentary change in 19.0% and moderate in 
36.3% of eyes. Most other ocular adverse events (including 
visual field defects, cataracts, ocular hyperemia) were mild to 
moderate in intensity, and occurred independent of presence 
of increased iris pigmentation.215
Compared with other topical ocular hypotensive medica-
tions, higher discontinuation rates were found for bimatoprost 
(5.3%) than for timolol (1.7%)123 and dorzolamide/timolol 
combination than for latanoprost,186 although similar for 
bimatoprost (3.3%) and FCDT (3.4%).132 Compared with 
latanoprost, ocular adverse effects were similar to dorzol-
amide.158 Ocular discomfort188 and stinging133 was greater 
with FCDT. Ocular hyperemia was found to be similar for 
brimonidine and latanoprost use in one review158 but converse 
in a meta-analysis.89 Serious ocular adverse events were 
similar between brimonidine and latanoprost; ocular inflam-
mation (0.7% vs 1.3%) and CME (0.3% vs 1.3%).89
Rates of non-compliance with glaucoma treatment 
instructions are as high as 50%.285 Persistency or maintenance 
of therapy, involves patient satisfaction with medication tol-
erability, physician satisfaction with IOP control,   medication Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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costs, ease of administration and patient understanding of 
long term medication use especially where an immediate 
effect is not noticed.212,286 The need for multiple medications 
with increasingly complex dosing regimens are real obstacles 
to good IOP control,285,287 and clearly once daily dosing of 
PGA is preferred.190
The Glaucoma Adherence and Persistence Study 
(GAPS) analyzed persistency of PGA monotherapy among 
6271 subjects followed for .12 months though retrospec-
tive review of pharmacy claims.211 Eleven percent of index 
latanoprost (n = 4071) patients continuously refilled their 
medication throughout the course of the year, as compared to 
9% of bimatoprost (n = 1199) patients and 5% of travoprost 
(n = 1001) subjects. Reasons for medication switch were 
lack of efficacy (43%) and adverse events (19%), especially 
hyperemia which accounted for 2/3 of adverse effect-related 
switches and 27% of discontinuations. Among subjects with 
hyperemia, 10% reported skipping doses due to red eyes, 30% 
claimed it was a problem when seeing other people, and 7% 
avoided social situations when their eyes were red.
A retrospective cohort study in 2003 of 28,741 claims 
records of patients on any topical ocular hypotensives 
found timolol prescribed most frequently (43%), followed 
by latanoprost (33%), and brimonidine (18%). Travoprost 
or bimatoprost were infrequently prescribed (1% each). 
Compared with latanoprost-treated patients, subjects treated 
with timolol, dorzolamide, travoprost, and bimatoprost were 
37%, 41%, 58% and 72% respectively more likely to discon-
tinue treatment, based on a single discontinuation event.286 
At 12 months, 23% of latanoprost-treated patients and 13% 
of patients treated with other ocular hypotensives had neither 
discontinued nor changed therapy.286 No association between 
co-payments and persistency was found.286
It is estimated that after 5 years of treatment, nearly 40% 
of glaucoma patients require 2 or more different   medications.4 
Availability of PGA combination therapy offers the advan-
tage of 2 classes of medication in a simplified regimen 
of 1 drop per day. In a survey of ophthalmologists in the 
European Union, 98% of doctors believed fixed combina-
tion therapy improved patient care by better compliance and 
quality of life (QoL).288 Other advantages include reduced 
washout if two or more drops are required, and reduced expo-
sure to corneal toxic preservatives. Chronic BAC exposure 
induced sub-clinical inflammation may be associated with 
glaucoma filtration surgery failure.289 Recently introduced, 
tafluprost is a fully preservative-free difluoroprostaglandin 
derivative of PGF2α. There are no published IOP-lowering 
efficacy rates of tafluprost compared with other topical 
ocular   hypotensive agents as yet, but no difference between 
preserved and   non-preserved formulations were found at 
4 weeks (P = 0.96)290 and ocular hyperemia rates were 
similar.291 TravatanZ® (Alcon Laboratories Inc, Forth Worth, 
TX) has the SofZia™ preservative system.292 TravatanZ 
retained equivalent efficacy as travoprost,293 and a lower non-
significant rate of ocular hyperemia was found for BAC-free 
travoprost (6.4%) than travoprost (9.0%).293
Existing estimates of the indirect costs of glaucoma 
are likely to underestimate the impact of visual field loss 
on functioning and QoL.294 Self-reported difficulty in using 
eye drops was strongly associated with decreased QoL, using 
the 25-item National Eye Institute Visual Function Question-
naire (VFQ-25) and short-form Health Survey (SF-12).295 
Using a non-validated questionnaire, patients showed pref-
erence for latanoprost for many systemic and ocular QoL 
measures compared with their previous therapy,296 also 
supported by studies where patients switched to latanoprost 
from monotherapy.297–299 A review has identified 4 major 
types of barriers to effective patient adherence: medication 
regimen, patient factors, provider factors, and situational or 
environmental factors.300 Interestingly, in this review, non-
adherence (defined by failure to fill a prescription over the 
initial 12 months) was 2 times higher in subjects initially 
started on a single agent compared with multiple agents,300 
contrary to other reports.190,285,287
Place of PGA in the management  
of OH and OAG
Lowering IOP is unequivocally associated with reduced 
rates of glaucoma and glaucoma progression as documented 
in several large multicenter trials including the OHTS,4 
the Early Manifest Glaucoma Trial,2,301 the   Collaborative 
  Normal-Tension Glaucoma Study Group,3,302 and the 
Advanced Glaucoma Intervention Study.303 Reduction in IOP 
is readily modifiable with topical ocular hypotensive agents, 
and these remain first-line treatment for OH and OAG.304,305 
If the IOP is not sufficiently lowered to the estimated pre-
defined target IOP level or if there is glaucomatous progres-
sion, then additional agents are introduced guided also by the 
patients concurrent health issues and medications, ability to 
comply, and potential impact on QoL. Surgery (laser, filter-
ing, or cyclodestructive surgery) may be warranted if topical 
ocular hypotensives are ineffective.
Although timolol was prescribed most frequently, fol-
lowed by latanoprost and brimonidine in a US study286 this 
choice may be governed by cost considerations, government 
or other institutional restrictions and familiarity by the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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  treating ophthalmologist.306 PGA have at least equivalent if 
not superior efficacy over timolol and other ocular hypoten-
sive agents, and advantages of once daily application and 
low risk of well-recognized life-threatening complica-
tions of β-blocker therapy such as bronchospasm, cardiac 
arrythmias, and exacerbation of congestive heart failure. 
Conjunctival hyperemia, the most common side effect 
of PGAs tend to be mild and reversible, but commonly 
encountered (up to 69% in one study with bimatoprost).85 
Cosmetic side effects such as eyelash growth, peri-ocular 
skin discoloration and iris pigmentation also occur but to 
a lesser extent.
The OHTS study documented that 39.7% of glaucoma 
patients require 2 or more different medications after 5 years 
of treatment.4 Simplifying dose regimen with fixed combina-
tions of 2 ocular hypotensive medications are preferred over 
concomitant administration.305 Fixed combination PGA with 
timolol also show superiority to monotherapy of its con-
stituent parts and equivalence to concomitant therapy to its 
constituent parts. Additional benefits include enhancement 
of adherence, reduction of medication wash-out effect, and 
minimization of preservative-toxicity on the ocular surface, 
although they should not be prescribed for patients with 
sensitivity to β-blocker therapy.
In summary, PGAs are powerful topical ocular hypoten-
sive agents available in our current OH and glaucoma treat-
ment armamentarium. The three main commercially available 
agents, latanoprost 0.005%, bimatoprost 0.03%, and travo-
prost 0.004% may differ in pharmacology,   tolerability and 
efficacy, but only a few meaningful differences   consistently 
demonstrated in studies using rigorous statistical and scien-
tific criteria exist.7 All three PGAs work primarily by the 
same prostanoid FP receptor although controversial. All 
three have fairly similar and superior effectiveness for IOP 
reduction than other topical hypotensive agents available. 
Additionally, 24-hour IOP control is better with PGAs than 
β-blockers. PGA have near absence of systemic side effects, 
although do have other commonly encountered side-effects 
including ocular hyperemia, iris pigmentation, eyelash 
growth, and peri-ocular pigmentary changes. Once daily 
administration and near absence of systemic side effects 
enhances tolerance and compliance. OH and OAG patients 
require lifelong treatment and follow-up care to halt progres-
sion of optic neuropathy, thus preserve remaining visual 
function and QoL.307
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